{"filings":[{"id":1112077,"accession_number":"0001731122-26-000871","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-06-17T20:32:20+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lunai Bioworks lands first defense contract, sues naked short sellers over 81.6% FTD shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Secured first revenue-generating multi-year defense collaboration via BioSymetrics for chemical threat assessment.","Formed Pathfinder Consortium with Harvard, Brigham & Women's, Purdue, Utah, Colorado for biodefense.","Partnered with BrainStorm Therapeutics; awarded $1.85M NIH STTR grant for alcohol use disorder.","Filed May 2026 lawsuit against unidentified parties; 29.6M fails-to-deliver (81.6% of shares); court granted expedited discovery.","Achieved compliance with Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1083560,"accession_number":"0001731122-26-000865","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-06-16T20:00:51+00:00","items":["8.01"],"status":"ready","headline":"Lunai Bioworks regains Nasdaq minimum bid price compliance; faces 1-year monitoring","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed Lunai Bioworks regained compliance with $1.00 minimum bid price rule (Rule 5550(a)(2)).","Company met terms set by Nasdaq Hearings Panel decisions dated April 20, 2026 and May 12, 2026.","Mandatory Panel monitor imposed for one year; no compliance plan or cure period if bid price drops again.","If non-compliant during monitor, Nasdaq will issue delist determination; company may request new hearing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":537676,"accession_number":"0001731122-26-000759","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-05-20T13:15:29+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lunai Bioworks announces 1-for-8 reverse stock split effective May 22, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio set at 1-for-8; stockholder approval obtained on May 8, 2026.","Shares outstanding will reduce from ~36.27M to ~4.53M; fractional shares rounded up.","Split aims to regain compliance with Nasdaq minimum bid price of $1.00 per share.","New CUSIP number 29350E302; trading symbol LNAI unchanged.","Previous 1-for-10 reverse split was effected on September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69683,"accession_number":"0001731122-26-000718","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-05-13T20:45:41+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve reverse stock split at ratio of 1-for-3 to 1-for-30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 (reverse split) approved: 13,571,288 for, 1,153,415 against, 61,177 abstentions.","Proposal 2 (adjournment) approved: 13,626,029 for, 1,091,528 against, 68,323 abstentions.","Exact split ratio between 1:3 and 1:30 to be set by Board; intended to regain Nasdaq bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":15642,"accession_number":"0001731122-26-000705","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K/A","filed_at":"2026-05-11T21:30:26+00:00","items":["3.01","5.07"],"status":"ready","headline":"Lunai Bioworks gets additional Nasdaq delisting notice for MVLS; completes $20M merger","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq staff determination on April 28, 2026 for non-compliance with $35M market value of listed securities (MVLS) rule.","Completed merger on May 1, 2026, issuing $20M Series B Preferred Stock to support compliance with equity rule.","Stockholders on May 8, 2026 approved reverse stock split authorization (1:3 to 1:30) to address bid price rule.","Company requests extension from Nasdaq Hearings Panel for bid price compliance; prior exception expires June 1, 2026.","Panel previously granted continued listing exception through May 1 (equity) and June 1 (bid price) subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93443,"accession_number":"0001731122-26-000653","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","2.01","9.01","3.01","3.02","3.03","5.03"],"status":"ready","headline":"Lunai Bioworks completes merger to acquire CNS patent portfolio; issues $20M Series B Preferred Stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired CNS patent portfolio via merger; issued $20M Series B Preferred Stock (no cash) to Oncotelic (62.5%) and Pelerin (37.5%).","Series B convertible at $1.50/share into up to 13.33M common shares; conversion requires stockholder approval under Nasdaq Rule 5635.","Patents cover Alzheimer's heterocyclic compounds, anti-TGF-beta agents, apomorphine, and intranasal delivery for CNS disorders.","Closed merger to address Nasdaq stockholders' equity deficiency; also needs bid price compliance by June 4, 2026; Panel decision pending.","Special meeting May 8 includes reverse split proposal for bid price compliance; conversion approval not on that ballot."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93442,"accession_number":"0001731122-26-000623","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lunai Bioworks postpones special meeting to May 8 to allow broker discretionary voting on reverse split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting postponed from May 4 to May 8, 2026 at 9:00 a.m. ET; virtual format unchanged.","Reason: Broadridge distributed proxy materials April 22; timing insufficient for broker discretionary voting under NYSE Rule 452.","Postponement allows brokers to vote uninstructed shares on routine matters (reverse stock split and adjournment proposals).","Record date remains April 10; previously submitted proxies will be voted unless revoked; internet/phone voting open until May 7.","Proposals include reverse stock split and adjournment; company seeks quorum and broker discretionary authority."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105061,"accession_number":"0001731122-26-000502","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Lunai Bioworks enters $20M strategic acquisition; exchanges $828K debt for equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Debt exchange: $828,770.14 principal and interest canceled for 3,909,293 shares at $0.21/share and warrants exercisable at $0.21 through 2036.","Enters $20M strategic transaction for BBB delivery platform and CNS Alzheimer's drug assets from Clemann Group.","Transaction structured as Series B Convertible Preferred at fixed $1.50 conversion price; no variable pricing or reset provisions.","Platform enables compounds to cross BBB, remain inactive systemically, and activate in the brain; targets acetylcholinesterase pathways.","CEO David Weinstein says transaction is a 'step-change' for CNS delivery capabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105060,"accession_number":"0001731122-26-000345","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Lunai Bioworks furloughs all US & Canada employees; CEO/CFO defer salaries amid cash crunch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All US and Canada employees placed on temporary furlough; will not work or receive compensation during furlough.","CEO and CFO voluntarily defer their salaries; employment terms otherwise unchanged.","Company maintains limited operations; has begun recalling some employees for platform development.","Furlough duration depends on securing additional capital; company actively seeking financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105059,"accession_number":"0001731122-26-000282","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq Panel grants Lunai Bioworks hearing on delisting; hearing set for March 26, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Delisting notice received Feb 6, 2026 from Nasdaq Staff; hearing request granted Feb 17, 2026.","Hearing before Nasdaq Hearings Panel scheduled for March 26, 2026.","Delisting action stayed pending Panel's final written decision.","No assurance that Panel will grant continued listing or that Company can maintain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105058,"accession_number":"0001731122-26-000221","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["3.01","7.01"],"status":"ready","headline":"Lunai Bioworks receives Nasdaq delisting notice; appeals hearing requested","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice received Feb 6, 2026: bid price closed below $1.00 for 30 consecutive business days through Feb 5, 2026.","Ineligible for 180-day compliance period due to 1-for-10 reverse stock split on Sep 30, 2025 (Nasdaq Rule 5810(c)(3)(A)(iv)).","Suspension and Form 25 filing scheduled for Feb 18, 2026 unless hearing request stays action.","Company timely requested hearing before Nasdaq Hearings Panel by Feb 13, 2026; outcome uncertain.","Delisting would deregister securities under Section 12(b) of Exchange Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121312,"accession_number":"0001731122-25-001625","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lunai Bioworks enters ATM sales agreement for up to $11.7M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Dawson James Securities for at-the-market offering of up to $11.7M in common stock.","Sales Agent receives 3.0% commission on gross proceeds; reimbursed for certain expenses.","Shares sold under effective S-3 registration statement (File No. 333-282898).","Company not obligated to sell any shares; may suspend or terminate at any time with 10 days' notice.","Net proceeds intended for general corporate purposes (per prospectus supplement)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121311,"accession_number":"0001731122-25-001597","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Lunai Bioworks raises $3.13M via private placement of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,133,333 shares at $1.00/share and 1,044,444 three-year warrants exercisable after 60 days to accredited investor.","Aggregate gross proceeds of $3,133,333; no underwriting discounts or commissions.","Issuance exempt under Section 4(a)(2) and Rule 506(b) of Regulation D; shares and warrants not registered.","Warrant exercise price not disclosed in the filing; shares subject to Rule 144 resale restrictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121310,"accession_number":"0001731122-25-001495","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lunai Bioworks regains Nasdaq compliance by holding annual meeting before deadline","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 7, 2025, Nasdaq notified Lunai of non-compliance for failing to hold annual meeting within one year of FY end.","Company held annual meeting on October 31, 2025, satisfying Listing Rule 5620(a).","Nasdaq confirmed compliance and closed the matter as of November 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121309,"accession_number":"0001731122-25-001465","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lunai Bioworks shareholders approve all four proposals at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected four directors: Weinstein, McNulty, Calder, Collins with >7M votes each; 1.3M broker non-votes.","Say-on-pay approved: 5.5M for, 2.2M against, 11.8K abstain.","Ratified Sadler, Gibb & Associates as auditor for FY2026: 8.8M for, 18K against.","Approved amendments to 2023 Equity Incentive Plan: 7.0M for, 574K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121308,"accession_number":"0001731122-25-001446","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lunai Bioworks receives Nasdaq notice for MVLS non-compliance; has 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["MVLS fell below $35M for 30 consecutive business days; compliance deadline is April 27, 2026.","To cure, MVLS must close at $35M or more for a minimum of 10 consecutive business days.","No immediate effect on trading; stock continues on Nasdaq Capital Market under LNAI.","Failure to cure could lead to delisting notice; company may appeal to Nasdaq Hearings Panel.","Company plans to monitor MVLS and consider potential corporate actions to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121307,"accession_number":"0001731122-25-001399","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Lunai Bioworks Regains Compliance with Nasdaq Bid Price Rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On April 14, 2025, Nasdaq notified Lunai of bid price deficiency; resolved as of Oct 15, 2025.","Closing bid price above $1.00 for 11 consecutive business days through Oct 14, 2025 satisfied Rule 5550(a)(2).","Company remains eligible for continued listing on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137964,"accession_number":"0001731122-25-001297","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-09-24T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Lunai Bioworks 1-for-10 reverse stock split effective Sept 29; new ticker LNAI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Share consolidation at 1-for-10 ratio begins 12:01 a.m. ET on September 29, 2025.","Outstanding shares will shrink from ~231.8M to ~23.2M; authorized shares unchanged at 350M.","Stockholders approved the split range (1:3 to 1:10) on August 15, 2025; board chose 1:10.","Common stock starts trading split-adjusted on Nasdaq Sept 30 under symbol LNAI; new CUSIP 29350E203.","Fractional shares rounded up to the next whole share; par value remains $0.0001 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137963,"accession_number":"0001731122-25-001204","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["8.01","2.06"],"status":"ready","headline":"Dutch court declares Lunai Bioworks subsidiary Gedi Cube B.V. bankrupt; impairment expected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Court of Amsterdam declared Gedi Cube B.V. bankrupt on Sept 2, 2025, after voluntary petition.","Lunai expects material impairment charge in Q3 2025; amount not yet estimable.","Management implementing contingency plans to mitigate supply chain and project disruptions.","Neither Lunai nor its other subsidiaries have filed for bankruptcy; operations continue as usual.","Receiver Mr. M.M. Dellebeke appointed to oversee Gedi bankruptcy proceedings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137969,"accession_number":"0001731122-25-001173","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Renovaro Inc. changes name to Lunai Bioworks Inc.; ticker remains RENB","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Amendment filed August 18, 2025; name change effective August 20, 2025.","New corporate name: Lunai Bioworks Inc. (formerly Renovaro Inc.).","Common stock continues trading on Nasdaq under ticker RENB; CUSIP will change.","No changes to fiscal year or other governance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137968,"accession_number":"0001731122-25-001076","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renovaro receives Nasdaq non-compliance notice for annual meeting; granted extension to Oct 31, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 7, 2025 for failure to comply with Listing Rule 5620(a) requiring annual shareholder meeting.","Nasdaq accepted compliance plan on August 5, 2025 and granted extension until October 31, 2025 to hold meeting.","Company intends to hold annual meeting within the extension period to regain compliance with listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137967,"accession_number":"0001731122-25-001030","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro Chairman Maurice van Tilburg resigns effective Aug 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maurice van Tilburg notified board of resignation as Chairman, effective Aug 22, 2025.","Resignation due to accepting leadership role at another company in unrelated sector; not due to disagreement.","Board thanks Tilburg for service; no successor named yet.","Tilburg will remain as Chairman until effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137966,"accession_number":"0001731122-25-000971","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renovaro receives Nasdaq delisting notice for missing annual meeting deadline; 45 days to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on July 7, 2025: company failed to hold annual meeting within 12 months of FY ended June 30, 2024.","Company has 45 calendar days from notice date to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant extension until December 29, 2025 to hold meeting.","Stock remains listed for now but failure to comply may lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137965,"accession_number":"0001731122-25-000948","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Renovaro exchanges $9.7M secured debt for $16.1M convertible notes, converted to 53.6M shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $9.7M in secured promissory notes for $16.1M in convertible notes (65% premium).","Convertible notes immediately converted into 53.6M shares at $0.30/share (premium to market).","Transaction eliminated $9.7M secured debt; no cash proceeds received by the company.","Conversion price exceeded July 7 closing price, so no Nasdaq stockholder approval needed.","Issuance to accredited existing shareholders exempt from registration under Section 4(a)(2)/Reg D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155355,"accession_number":"0001731122-25-000829","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro subsidiary GEDi Cube CEO Maurice van Tilburg resigns; remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maurice van Tilburg resigned as CEO of GEDi Cube B.V., a wholly-owned indirect subsidiary, effective May 30, 2025.","Resignation is not related to any disagreement with Renovaro or its Board.","Mr. van Tilburg will continue to serve on Renovaro Inc.'s Board of Directors.","No permanent replacement for GEDi Cube CEO has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155354,"accession_number":"0001731122-25-000592","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renovaro receives Nasdaq deficiency notice for low bid price; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notice dated April 14, 2025 for failure to maintain $1 minimum bid price over 30 consecutive business days.","Initial compliance period ends October 13, 2025; must close at $1.00 for 10 consecutive days.","If not cured, may qualify for second 180-day period if meeting other listing standards.","Stock continues trading under symbol RENB; Company evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155353,"accession_number":"0001731122-25-000562","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Renovaro completes acquisition of Biosymetrics, issues 15M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consummated merger with Biosymetrics on April 8, 2025; Biosymetrics becomes wholly owned subsidiary.","Issued 15.0 million shares of Renovaro common stock to former Biosymetrics stockholders.","Shares issued in reliance on Section 4(a)(2) exemption based on accredited investor representations.","Transaction was previously announced on February 26, 2025 via Merger Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173870,"accession_number":"0001731122-25-000354","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Renovaro Extends LOI with Predictive Oncology, Acquires Shares for $500,000","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Renovaro and Predictive Oncology extended the LOI termination date from February 28, 2025 to March 31, 2025.","Renovaro acquired 467,290 shares of Predictive Oncology common stock for $500,000 at $1.07 per share.","Renovaro agreed to purchase an additional 901,298 shares for $964,389 upon execution of a definitive merger agreement.","The amendment eliminated Renovaro's obligation to acquire certain shares under the original warrant exercise provision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173869,"accession_number":"0001731122-25-000312","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Renovaro enters definitive merger with AI-driven Biosymetrics for 15M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Renovaro issues 15M unregistered common shares to Biosymetrics stockholders for all outstanding shares; lock-up of CEO shares for 1 year.","3M of the issued shares held in escrow for 1 year to satisfy potential indemnification claims.","Merger expected to close by March 15, 2025, subject to Biosymetrics stockholder approval and Nasdaq listing.","Biosymetrics' Elion AI platform has partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures.","Combined entity to focus on AI-driven biomarker discovery and precision medicine in cancer and other diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173868,"accession_number":"0001731122-25-000248","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Renovaro restates multiple prior financials due to warrant accounting error","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee determined misstatements in Q3 FY2024, FY2024, and Q1 FY2025 filings over warrant exercises in March 2024.","Warrant exercises were not properly reflected as change in fair value of contingent consideration.","Company will amend the three filings as soon as practicable; prior reports should no longer be relied upon.","Restatement affects unaudited interim and audited annual consolidated financial statements.","Non-reliance extends to related press releases, shareholder communications, and investor presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173867,"accession_number":"0001731122-25-000191","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro subsidiary GEDi Cube enters amended CEO employment agreement with Maurice van Tilburg","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Monthly salary of €22,080 (~$22,806) for van Tilburg as GEDi Cube CEO.","Eligible for annual bonus up to €96,000 (~$99,158) based on board-determined performance goals.","Van Tilburg to participate in share option plan and A.S.R. Nederland collective pension plan.","Entitled to 20 working days holiday per year plus holiday allowance of 8% of gross salary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173866,"accession_number":"0001731122-25-000067","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro appoints Nathen Fuentes as CFO; removes interim CFO Simon Tarsh","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathen Fuentes, age 42, appointed CFO effective January 6, 2025; previously CFO at Telomir Pharmaceuticals (Sep 2023 – Jun 2024).","Base salary of $280,000 per year; performance bonus up to $40,000 annually, pro-rated for 2025.","Equity incentive grant of 250,000 stock options vesting quarterly over eight quarters; discretionary equity grant on first anniversary.","If terminated without cause or for good reason: six months base salary, COBRA reimbursement for 6 months, accelerated vesting of time-based awards.","Simon Tarsh removed as Interim CFO in connection with Fuentes' appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173865,"accession_number":"0001731122-25-000037","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Renovaro signs binding LOI to buy Predictive Oncology; preferred stock valued at $3/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["POAI shareholders to receive new Renovaro preferred stock in 1:1 exchange; preferred stock redeemable at $3.00 per share after 18 months.","Deal conditions include minimum $15M fundraising by Renovaro and POAI shareholder approval; definitive agreement due by Feb 28, 2025.","If POAI warrants not exercised by Jan 15, Renovaro will buy up to 2.33M POAI common shares at $1.07 each.","Transaction provides access to POAI's biobank of 150,000 tumor specimens and AI platform with 92% drug-response accuracy.","Combined entity aims to launch decision-support platform for oncologists in 2025, integrating multi-omic diagnostics and drug discovery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173864,"accession_number":"0001731122-25-000017","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro appoints Maurice van Tilburg as CEO of subsidiary GEDi Cube","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maurice van Tilburg, age 53, appointed CEO of GEDi Cube, wholly owned subsidiary of Renovaro, effective Dec 30, 2024.","Van Tilburg is a current board member; previously CEO of Euronext Amsterdam and director at Dutch National Growth Fund.","Base salary $300,000/year; eligible for performance bonus up to $100,000/year.","Sign-on bonus of 250,000 restricted shares and 1,000,000 stock options (200,000 vest per year for 5 years).","Severance: 6 months base salary, COBRA reimbursement for 6 months, accelerated equity vesting if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190839,"accession_number":"0001731122-24-001842","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro COO Francois Binette resigns effective Nov 22, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Francois Binette PhD tendered resignation as COO on Nov 15, 2024.","Effective date of departure is November 22, 2024.","No successor named; interim arrangements not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190838,"accession_number":"0001731122-24-001750","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Renovaro amends consulting agreement with Interim CFO Simon Tarsh; $25k/month plus options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Tarsh continues as Interim CFO under amended agreement; monthly fee $25,000.","Tarsh received $29,063 bonus on Oct 31 and will receive another $29,063 on Nov 30.","Granted 58,500 stock options under 2023 Equity Incentive Plan; vest if new CFO hired before termination.","Agreement term is 3 months, renewable monthly; either party may terminate on 30 days notice.","Tarsh eligible for target bonus up to 30% of total consideration if milestones achieved (timely SEC filings and new CFO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190836,"accession_number":"0001731122-24-001672","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K/A","filed_at":"2024-10-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Renovaro assigns committee roles to four directors effective Oct 23, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Maurice van Tilburg appointed to Nominating & Governance and Special Litigation committees.","James A. McNulty named Audit Committee Chair, also on Compensation and Special Litigation.","Douglas W. Calder joins Audit, Nominating & Governance, and Compensation committees.","Mark A. Collins, PhD, appointed to Audit and Special Litigation committees.","All directors will enter standard indemnification agreements with the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190837,"accession_number":"0001731122-24-001606","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["3.01","5.02","9.01"],"status":"ready","headline":"Renovaro appoints new CEO David Weinstein; multiple board resignations including chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Weinstein (age 64) appointed CEO and board member; base salary $400k, up to $150k bonus, 250k restricted shares, 1.6M stock options.","Former CEO Mark Dybul resigned Oct 12, 2024; eight directors resigned between Oct 11-15, including chairman Rene Sindlev.","New directors appointed: Maurice van Tilburg, James McNulty, Douglas Calder, Mark Collins.","Weinstein receives $25k bonus if company secures $2M+ in new financing; severance includes 6 months' salary and accelerated equity vesting.","Resignations by James Sapirstein, Gregg Alton, Jayne McNicol, Carol Brosgart were by letters; no disagreements cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207319,"accession_number":"0001731122-24-001431","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Renovaro receives Nasdaq deficiency notice for bid price below $1; 180-day cure period","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Renovaro on Sept 12, 2024 that stock failed minimum $1 bid price for 30 consecutive business days.","Company has 180 calendar days (until March 11, 2025) to regain compliance by closing at or above $1 for 10 consecutive days.","If not cured, Renovaro may qualify for an additional 180-day period by meeting other listing standards.","Stock continues trading under symbol RENB; company is evaluating options to regain bid price compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207318,"accession_number":"0001731122-24-001372","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Renovaro seeks strategic investors for up to 20% of subsidiary Cube","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board intends to offer up to 20% ownership in RenovaroCube, a wholly owned molecular data science subsidiary.","Cube uses proprietary AI for multi-omics analysis to accelerate precision medicine, starting with cancer.","Proceeds from the offering expected to advance Cube's platform and go-to-market strategy.","Subscription terms to be determined as investors are identified and approved by Renovaro's Board.","RenovaroBio continues work on patented cancer vaccine targeting pancreatic, head and neck, liver tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207317,"accession_number":"0001731122-24-001283","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["4.02","7.01"],"status":"ready","headline":"Renovaro restates Q1 2024 financials due to IPR&D asset impairment error; files lawsuit for fraud","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Concluded Q1 2024 financials contained material misstatement in IPR&D asset impairment; assets overstated, net loss understated.","Error linked to termination of License Agreement for RENB-HV-01, which was deprioritized and terminated by licensor.","Company will restate Q1 2024 Form 10-Q, expects to file amended report week of Aug 19, 2024.","Filed suit against Weird Science LLC and others alleging fraudulent concealment of murder-for-hire scheme to induce 2018 merger.","Seeks equitable relief including return of shares received in merger and damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207316,"accession_number":"0001731122-24-001085","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Leni Boeren resigns from Renovaro board effective June 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leni Boeren resigned as director and chair of the special litigation committee on June 27, 2024.","Resignation due to family health reasons; no disagreement with company’s management or policies.","No replacement named; board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224722,"accession_number":"0001731122-24-001001","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Renovaro closes $10M private placement of common stock and warrants at $1.4726/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 6,421,256 units (1 share + 1/10 warrant) at $1.4726 each, raising ~$9.45M in cash and debt conversions.","Cash proceeds of $5.8M from one investor; $478k cash plus $3.19M note conversion from second; $66k cash plus $468k note from third.","Warrants exercisable at $1.4726 per share for 5 years, representing 10% dilution on exercised shares.","Net proceeds allocated for general corporate purposes.","CEO comments on potential future grants, loans, subsidies from US and European institutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224721,"accession_number":"0001731122-24-000883","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Renovaro amends bylaws to update corporate name and officer titles","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws effective May 21, 2024.","Bylaws updated to reflect company name as Renovaro Inc.","Titles of corporate officers revised throughout the document."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224720,"accession_number":"0001731122-24-000877","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Renovaro signs MoU with Amsterdam UMC to form joint cancer immunotherapy company","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Signed MoU to establish Newco in Netherlands for personalized cancer immunotherapy.","Combines Renovaro's proprietary dendritic vaccine tech with Amsterdam UMC's immunomodulatory expertise.","Newco to be headquartered in Amsterdam; clinical activities may move there.","Final commitments subject to due diligence and approval from both executive boards.","No financial terms or deal value disclosed in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224719,"accession_number":"0001731122-24-000716","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"RenovaroCube unveils Flamingo AI model for early multi-cancer detection via fragmentomics","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Flamingo uses ultra-low pass WGS of cfDNA; requires as few as 200,000 fragments per sample.","Model integrates fragment lengths, sequence motifs, and neural network to distinguish cancer vs. healthy.","Part of The Cube platform, combining multi-omic data for comprehensive early detection and monitoring.","RenovaroCube is wholly owned by Renovaro (Nasdaq: RENB); Cyclomics acquisition previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224718,"accession_number":"0001731122-24-000683","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"RenovaroCube to acquire remaining 25% of Cyclomics for 100% ownership in cancer diagnostics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["RenovaroCube amends LOI to acquire full 100% ownership of Cyclomics (was 75%).","Deal strengthens AI-driven early cancer detection; combines CyclomicsSeq and OmniOmics 4th-gen tech.","Collaborations with Oxford Nanopore and Nvidia provide sequencing, supercomputing, and AI software.","Technology aims to detect a single ctDNA molecule in blood with nearly 100% accuracy.","RenovaroCube's Cube platform has over 3,600 biomarker panels for 13 cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224717,"accession_number":"0001731122-24-000681","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K/A","filed_at":"2024-04-24T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Renovaro Cube audited: €2.1M net loss post-acquisition, going concern noted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Successor period (Aug 24–Dec 31, 2023) net loss of €2,100,579, no revenue generated.","Accumulated deficit of €2,100,579; cash only €114,520 at Dec 31, 2023.","Auditor includes going-concern explanatory paragraph citing negative operating cash flows and deficit.","Predecessor (Grace Systems) net loss €129,572 for Jan 1–Aug 23, 2023 and €623,982 for FY 2022.","Acquisition of Grace Systems by Renovaro Cube treated as asset acquisition; company in development stage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243991,"accession_number":"0001731122-24-000419","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Renovaro appoints Simon Tarsh as Interim CFO; outgoing CFO Puche departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Simon Tarsh named Interim CFO effective March 11, 2024; replaces Ms. Puche who leaves after >5 years.","Consulting agreement pays Tarsh PB Advisors $25,000/month plus up to 30% bonus on milestones.","Bonuses tied to timely SEC filings and hiring a permanent CFO before agreement termination.","Term is 6 months, renewable monthly; may be terminated by either party on 30 days' notice.","Tarsh receives 10,000 stock options, vesting if a new CFO is hired prior to termination date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243990,"accession_number":"0001731122-24-000372","cik":1527728,"company_name":"Lunai Bioworks Inc.","ticker":"LNAI","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Renovaro receives termination notice for License Agreement covering HIV candidate RENB-HV-01","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Weird Science LLC terminated the License Agreement for RENB-HV-01 on March 1, 2024.","Renovaro had previously deprioritized RENB-HV-01 as costly and long-term, focusing on faster pipelines.","Lead candidate is now RENB-DC-11, a potential cancer vaccine for solid tumors; HIV programs continue under other licenses.","Company is evaluating all options regarding the termination and does not acknowledge the termination as effective."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13147827.83236641,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-03-07T23:59:59+00:00|243990"}